Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Hematologic Neoplasms 4Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Lung Neoplasms 1Hypogonadism 1Hematopoietic and Lymphatic System Neoplasm 1Heart Failure 1Colitis 1Central Nervous System Neoplasms 1Cardiomyopathies 1Carcinoma, Non-Small-Cell Lung 1Anemia, Aplastic 1

Interventions

ibrutinib 1fludarabine phosphate 1Whole-Body Irradiation 1Tacrolimus 1Standard of Care 1Rituximab 1Practice Guidelines as Topic 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anemia, Aplastic × Practice Guidelines as Topic × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡